Shanghai Institute of Materia Medica (SIMM)
↗Shanghai, China
The Shanghai Institute of Materia Medica (SIMM) is a premier, government-funded research institution under the Chinese Academy of Sciences (CAS), focused on comprehensive drug discovery and development. Founded in 1932, it is one of China's oldest and most prominent research centers for pharmaceutical innovation, bridging basic and applied research to develop new therapies for major diseases.
SIMM operates as a major hub for translational medicine, collaborating extensively with domestic and international pharmaceutical companies, universities, and research institutions. Its research priorities span oncology, cardio-cerebrovascular diseases, neuropsychiatric disorders, metabolic diseases, autoimmune diseases, infectious diseases, and the modernization of Traditional Chinese Medicine (TCM).
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Drug Discovery and Development Research Institute
SIZE & FINANCIALS
Employees:1001-5000
Founded:1932
Ownership:government
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Commercial
Modalities:Small molecule, ADC, PROTAC, Biological products
Active Trials:162
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Chinese Academy of Sciences (CAS)
Key Partnerships:Johnson & Johnson (BTK degraders), Simcere Pharmaceutical, Crown Bioscience, Servier
COMPETITION
Position:Leader
LINKS
Website:simm.ac.cn
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Shanghai Institute of Materia Medica (SIMM) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shanghai Institute of Materia Medica (SIMM). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.